IO Biotech (IOBT) News Today → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free IOBT Stock Alerts $1.18 -0.06 (-4.84%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 27, 2024 | finance.yahoo.comWill IO Biotech (NASDAQ:IOBT) Spend Its Cash Wisely?May 23, 2024 | globenewswire.comIO Biotech to Present at Jefferies Global Healthcare ConferenceMay 17, 2024 | marketbeat.comResearch Analysts Offer Predictions for IO Biotech, Inc.'s Q2 2024 Earnings (NASDAQ:IOBT)IO Biotech, Inc. (NASDAQ:IOBT - Free Report) - Equities research analysts at HC Wainwright upped their Q2 2024 earnings per share estimates for IO Biotech in a research note issued on Wednesday, May 15th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per shareMay 15, 2024 | markets.businessinsider.comOptimistic Buy Rating for IO Biotech Amidst Promising Clinical Trial Progress and Accelerated PFS Data TimelineMay 15, 2024 | marketbeat.comHC Wainwright Boosts IO Biotech (NASDAQ:IOBT) Price Target to $12.00HC Wainwright increased their price objective on shares of IO Biotech from $8.00 to $12.00 and gave the company a "buy" rating in a research report on Wednesday.May 15, 2024 | insidertrades.comInsider Selling: IO Biotech, Inc. (NASDAQ:IOBT) Major Shareholder Sells 658,809 Shares of StockMay 15, 2024 | marketbeat.comIO Biotech, Inc. (NASDAQ:IOBT) Major Shareholder Holdings A/S Novo Sells 658,809 SharesIO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) major shareholder Holdings A/S Novo sold 658,809 shares of the business's stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $1.22, for a total value of $803,746.98. Following the completion of the transaction, the insider now directly owns 4,429,449 shares of the company's stock, valued at $5,403,927.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.May 14, 2024 | investorplace.comIOBT Stock Earnings: IO Biotech Beats EPS for Q1 2024May 14, 2024 | globenewswire.comIO Biotech Reports First Quarter 2024 Financial Results and Provides Business HighlightsMay 12, 2024 | marketbeat.comIO Biotech, Inc. (NASDAQ:IOBT) Sees Significant Drop in Short InterestIO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) was the recipient of a significant drop in short interest in the month of April. As of April 30th, there was short interest totalling 39,500 shares, a drop of 36.1% from the April 15th total of 61,800 shares. Based on an average daily volume of 135,000 shares, the short-interest ratio is presently 0.3 days. Currently, 0.1% of the shares of the company are sold short.April 29, 2024 | marketbeat.comShort Interest in IO Biotech, Inc. (NASDAQ:IOBT) Declines By 9.4%IO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) was the recipient of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 61,800 shares, a decline of 9.4% from the March 31st total of 68,200 shares. Approximately 0.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 133,900 shares, the days-to-cover ratio is currently 0.5 days.April 24, 2024 | globenewswire.comIO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 17, 2024 | msn.comIO Biotech (IOBT) Price Target Decreased by 11.11% to 8.16April 15, 2024 | globenewswire.comIO Biotech Expands Senior Leadership Team to Progress Commercialization ReadinessApril 11, 2024 | investing.comIO Biotech presents cancer vaccine data at AACRApril 9, 2024 | globenewswire.comIO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103April 5, 2024 | globenewswire.comIO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business OfficerMarch 29, 2024 | marketbeat.comIO Biotech, Inc. (NASDAQ:IOBT) Short Interest Up 50.3% in MarchIO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) was the recipient of a large growth in short interest in March. As of March 15th, there was short interest totalling 81,600 shares, a growth of 50.3% from the February 29th total of 54,300 shares. Based on an average daily trading volume, of 144,900 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.2% of the shares of the stock are sold short.March 18, 2024 | marketbeat.comShort Interest in IO Biotech, Inc. (NASDAQ:IOBT) Rises By 10.4%IO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) was the target of a significant growth in short interest during the month of February. As of February 29th, there was short interest totalling 54,300 shares, a growth of 10.4% from the February 14th total of 49,200 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average daily volume of 148,200 shares, the days-to-cover ratio is currently 0.4 days.March 11, 2024 | marketbeat.comAnalysts Offer Predictions for IO Biotech, Inc.'s Q1 2024 Earnings (NASDAQ:IOBT)IO Biotech, Inc. (NASDAQ:IOBT - Free Report) - Stock analysts at HC Wainwright issued their Q1 2024 earnings per share estimates for IO Biotech in a research note issued to investors on Wednesday, March 6th. HC Wainwright analyst E. Bodnar expects that the company will earn ($0.38) per share forMarch 7, 2024 | finance.yahoo.comIO Biotech Inc (IOBT) Reports Year-End Financial Results and Progress in Clinical TrialsMarch 6, 2024 | markets.businessinsider.comBuy Recommendation for IO Biotech on Strong Data Prospects and Undervalued Stock PositionMarch 6, 2024 | morningstar.comIO Biotech Inc IOBTMarch 6, 2024 | msn.comIO Biotech GAAP EPS of -$0.40 misses by $0.02March 6, 2024 | globenewswire.comIO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual MeetingMarch 6, 2024 | marketbeat.comIO Biotech (NASDAQ:IOBT) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reissued a "buy" rating and issued a $8.00 price target on shares of IO Biotech in a research report on Wednesday.March 5, 2024 | investorplace.comIOBT Stock Earnings: IO Biotech Misses EPS for Q4 2023March 5, 2024 | globenewswire.comIO Biotech Announces 2023 Fourth-Quarter and Year-End ResultsMarch 3, 2024 | marketbeat.comArmistice Capital LLC Buys New Shares in IO Biotech, Inc. (NASDAQ:IOBT)Armistice Capital LLC bought a new stake in shares of IO Biotech, Inc. (NASDAQ:IOBT - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,148,000 shares of the company's stock, valued at apFebruary 26, 2024 | globenewswire.comIO Biotech to Present at 44th Annual Cowen Health Care ConferenceFebruary 6, 2024 | marketbeat.comVivo Capital LLC Has $8.71 Million Stake in IO Biotech, Inc. (NASDAQ:IOBT)Vivo Capital LLC grew its holdings in shares of IO Biotech, Inc. (NASDAQ:IOBT - Free Report) by 104.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,173,439 shares of the company's stock afFebruary 4, 2024 | msn.comWhat's Next for Iovance Biotherapeutics Stock?January 15, 2024 | finance.yahoo.comIO Biotech, Inc. (NASDAQ:IOBT) most popular amongst private equity firms who own 61% of the shares, institutions hold 24%January 3, 2024 | marketbeat.comIO Biotech, Inc. (NASDAQ:IOBT) Short Interest UpdateIO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) was the recipient of a significant decrease in short interest in the month of December. As of December 15th, there was short interest totalling 185,500 shares, a decrease of 7.7% from the November 30th total of 200,900 shares. Currently, 0.5% of the company's shares are short sold. Based on an average daily trading volume, of 126,000 shares, the days-to-cover ratio is currently 1.5 days.January 3, 2024 | seekingalpha.comIO Biotech: A Phase 3 Company Getting No RespectDecember 21, 2023 | finance.yahoo.comIO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket TrialDecember 19, 2023 | finance.yahoo.comWe're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn RateNovember 27, 2023 | msn.comIO Biotech executive discloses purchase of 10K sharesNovember 24, 2023 | seekingalpha.comIOBT IO Biotech, Inc.November 15, 2023 | investing.comIO Biotech earnings beat, revenue was in line with estimatesNovember 15, 2023 | markets.businessinsider.comPromising Clinical Trials and Favorable Safety Profile Drives Buy Rating for IO BiotechNovember 14, 2023 | benzinga.comIO Biotech Stock (NASDAQ:IOBT) Earnings Dates and Earning CallsNovember 13, 2023 | msn.comIO Biotech GAAP EPS of -$0.43 misses by $0.10November 13, 2023 | benzinga.comIO Biotech: Q3 Earnings InsightsNovember 13, 2023 | finance.yahoo.comIO Biotech Announces 2023 Third Quarter ResultsNovember 10, 2023 | finance.yahoo.comIO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced MelanomaNovember 7, 2023 | finance.yahoo.comThis IO Biotech Insider Increased Their Holding In The Last YearNovember 1, 2023 | tmcnet.comIO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual MeetingNovember 1, 2023 | finance.yahoo.comIO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingOctober 23, 2023 | finance.yahoo.comEncouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) Congress Get IO Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter. Email Address Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached. Secure Your Spot Now IOBT Media Mentions By Week IOBT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IOBT News Sentiment▼1.200.76▲Average Medical News Sentiment IOBT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IOBT Articles This Week▼21▲IOBT Articles Average Week Get IO Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: aTyr Pharma News Today DURECT News Today Alto Neuroscience News Today Nkarta News Today UroGen Pharma News Today Q32 Bio News Today Nanobiotix News Today Atea Pharmaceuticals News Today Kamada News Today XOMA News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IOBT) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBuy this small stock before coming AI Tidal WaveChaikin AnalyticsWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IO Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
